Shandong Sinobioway Biomedicine Co Ltd (002581) - Net Assets
Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) has net assets worth CN¥1.99 Billion CNY (≈ $291.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.21 Billion ≈ $324.07 Million USD) and total liabilities (CN¥221.51 Million ≈ $32.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shandong Sinobioway Biomedicine Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.99 Billion |
| % of Total Assets | 90.0% |
| Annual Growth Rate | 20.58% |
| 5-Year Change | -7.68% |
| 10-Year Change | -5.67% |
| Growth Volatility | 75.96 |
Shandong Sinobioway Biomedicine Co Ltd - Net Assets Trend (2007–2024)
This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002581 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below shows the annual net assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024. For live valuation and market cap data, see 002581 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.02 Billion ≈ $295.93 Million |
-6.97% |
| 2023-12-31 | CN¥2.17 Billion ≈ $318.08 Million |
-11.94% |
| 2022-12-31 | CN¥2.47 Billion ≈ $361.21 Million |
-0.04% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.34 Million |
+12.72% |
| 2020-12-31 | CN¥2.19 Billion ≈ $320.56 Million |
-8.30% |
| 2019-12-31 | CN¥2.39 Billion ≈ $349.56 Million |
-15.29% |
| 2018-12-31 | CN¥2.82 Billion ≈ $412.66 Million |
-3.37% |
| 2017-12-31 | CN¥2.92 Billion ≈ $427.04 Million |
+15.47% |
| 2016-12-31 | CN¥2.53 Billion ≈ $369.84 Million |
+17.89% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.71 Million |
+186.07% |
| 2014-12-31 | CN¥749.40 Million ≈ $109.66 Million |
+1.50% |
| 2013-12-31 | CN¥738.31 Million ≈ $108.04 Million |
+4.81% |
| 2012-12-31 | CN¥704.41 Million ≈ $103.08 Million |
+4.78% |
| 2011-12-31 | CN¥672.28 Million ≈ $98.38 Million |
+279.09% |
| 2010-12-31 | CN¥177.34 Million ≈ $25.95 Million |
+36.73% |
| 2009-12-31 | CN¥129.71 Million ≈ $18.98 Million |
+11.70% |
| 2008-12-31 | CN¥116.12 Million ≈ $16.99 Million |
+38.34% |
| 2007-12-31 | CN¥83.94 Million ≈ $12.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Sinobioway Biomedicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1254.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥675.55 Million | 35.12% |
| Common Stock | CN¥229.15 Million | 11.91% |
| Other Components | CN¥1.02 Billion | 52.97% |
| Total Equity | CN¥1.92 Billion | 100.00% |
Shandong Sinobioway Biomedicine Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Sinobioway Biomedicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Udemy Inc
NASDAQ:UDMY
|
$651.67 Million |
|
Hubei Kailong Chemical Group Co Ltd
SHE:002783
|
$651.80 Million |
|
Intellian Technologies Inc
KQ:189300
|
$651.92 Million |
|
Song Da Urban & Industrial Zone Investment and Development JSC
VN:SJS
|
$652.14 Million |
|
New East New Materials Co Ltd
SHG:603110
|
$651.64 Million |
|
Shore Bancshares Inc
NASDAQ:SHBI
|
$651.56 Million |
|
SI-TECH Information Technology Co Ltd
SHE:300608
|
$651.45 Million |
|
Afya Ltd
NASDAQ:AFYA
|
$651.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Sinobioway Biomedicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,068,467,729 to 1,923,634,393, a change of -144,833,336 (-7.0%).
- Net loss of 137,313,572 reduced equity.
- Dividend payments of 177,360 reduced retained earnings.
- Other comprehensive income decreased equity by 169,400,534.
- Other factors increased equity by 162,058,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-137.31 Million | -7.14% |
| Dividends Paid | CN¥177.36K | -0.01% |
| Other Comprehensive Income | CN¥-169.40 Million | -8.81% |
| Other Changes | CN¥162.06 Million | +8.42% |
| Total Change | CN¥- | -7.00% |
Book Value vs Market Value Analysis
This analysis compares Shandong Sinobioway Biomedicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 14.52x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.46 | CN¥6.75 | x |
| 2008-12-31 | CN¥0.58 | CN¥6.75 | x |
| 2009-12-31 | CN¥0.61 | CN¥6.75 | x |
| 2010-12-31 | CN¥0.84 | CN¥6.75 | x |
| 2011-12-31 | CN¥2.66 | CN¥6.75 | x |
| 2012-12-31 | CN¥2.49 | CN¥6.75 | x |
| 2013-12-31 | CN¥2.64 | CN¥6.75 | x |
| 2014-12-31 | CN¥1.97 | CN¥6.75 | x |
| 2015-12-31 | CN¥4.65 | CN¥6.75 | x |
| 2016-12-31 | CN¥3.74 | CN¥6.75 | x |
| 2017-12-31 | CN¥4.33 | CN¥6.75 | x |
| 2018-12-31 | CN¥4.17 | CN¥6.75 | x |
| 2019-12-31 | CN¥3.50 | CN¥6.75 | x |
| 2020-12-31 | CN¥3.21 | CN¥6.75 | x |
| 2021-12-31 | CN¥3.62 | CN¥6.75 | x |
| 2022-12-31 | CN¥3.62 | CN¥6.75 | x |
| 2023-12-31 | CN¥3.14 | CN¥6.75 | x |
| 2024-12-31 | CN¥8.39 | CN¥6.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Sinobioway Biomedicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.10%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.14x
- Recent ROE (-7.14%) is below the historical average (12.27%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 38.88% | 21.75% | 1.57x | 1.14x | CN¥24.24 Million |
| 2008 | 31.90% | 20.90% | 1.23x | 1.24x | CN¥25.43 Million |
| 2009 | 45.35% | 27.51% | 1.30x | 1.27x | CN¥45.85 Million |
| 2010 | 39.62% | 28.42% | 1.18x | 1.18x | CN¥52.52 Million |
| 2011 | 9.96% | 27.19% | 0.36x | 1.03x | CN¥-251.66K |
| 2012 | 12.25% | 30.23% | 0.39x | 1.03x | CN¥15.83 Million |
| 2013 | 11.92% | 27.75% | 0.41x | 1.05x | CN¥14.21 Million |
| 2014 | 10.87% | 25.53% | 0.41x | 1.03x | CN¥6.54 Million |
| 2015 | 12.00% | 29.16% | 0.36x | 1.16x | CN¥41.78 Million |
| 2016 | 16.91% | 33.02% | 0.47x | 1.09x | CN¥170.75 Million |
| 2017 | 13.60% | 33.41% | 0.29x | 1.40x | CN¥102.75 Million |
| 2018 | -3.48% | -14.41% | 0.15x | 1.56x | CN¥-371.09 Million |
| 2019 | 2.74% | 11.17% | 0.17x | 1.48x | CN¥-167.81 Million |
| 2020 | -9.25% | -70.78% | 0.11x | 1.15x | CN¥-407.66 Million |
| 2021 | 11.35% | 67.29% | 0.15x | 1.15x | CN¥32.18 Million |
| 2022 | -0.62% | -4.11% | 0.12x | 1.20x | CN¥-253.23 Million |
| 2023 | -16.07% | -77.35% | 0.18x | 1.13x | CN¥-539.31 Million |
| 2024 | -7.14% | -38.10% | 0.16x | 1.14x | CN¥-329.68 Million |
Industry Comparison
This section compares Shandong Sinobioway Biomedicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Sinobioway Biomedicine Co Ltd (002581) | CN¥1.99 Billion | 38.88% | 0.11x | $651.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Shandong Sinobioway Biomedicine Co Ltd
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more